Table 2 Patient characteristics
Age, median (range) | 63 (39–76) years |
Male/female | 12/9 |
Performance score | |
0 | 8 (38%) |
1 | 13 (62%) |
Site of primary tumour | |
Colon | 15 (71%) |
Rectum | 6 (29%) |
Site of disease | |
Primary | 8 (38%) |
Liver | 18 (86%) |
Lungs | 14 (67%) |
Lymph nodes | 8 (38%) |
Bones | 4 (19%) |
Soft tissue | 3 (14%) |
Peritoneum | 1 (5%) |
Tumour load | |
Baseline sum diameters of all lesions per patient, median (range) | 27.6 (9.2–111.0) cm |
Prior treatment | |
Surgery | 17 (81%) |
Chemotherapy | 21 (100%) |
Bevacizumab | 17 (81%) |
Anti-EGFR therapy | 7 (33%) |
External radiotherapy | 6 (29%) |
CEA plasma level | |
Baseline, median (range) | 120 (12–2200) μg l−1 |
Administered 177 Lu-activity dose | |
Median (range) | 5.6 (2.5–7.4) GBq |
